Bristol Myers, bluebird bio have their BCMA CAR-T nod, but latecomer J&J could have an advantage: analysts

Bluebird bio and partner Bristol Myers Squibb have outrun Johnson & Johnson and Legend Biotech in snagging the first FDA nod for a BCMA-targeted CAR-T therapy. But the label of the new drug, dubbed Abecma, could hand its upcoming competitor an advantage, analysts say.